version 17b Search Results


pet-17b  (Merck KGaA)
90
Merck KGaA pet-17b
Pet 17b, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pet-17b/product/Merck KGaA
Average 90 stars, based on 1 article reviews
pet-17b - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
program version 17b  (STATA Corporation)
90
STATA Corporation program version 17b
Program Version 17b, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/program version 17b/product/STATA Corporation
Average 90 stars, based on 1 article reviews
program version 17b - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
jmp version 9.0.0  (SAS institute)
90
SAS institute jmp version 9.0.0
Jmp Version 9.0.0, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/jmp version 9.0.0/product/SAS institute
Average 90 stars, based on 1 article reviews
jmp version 9.0.0 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
7500 real-time (2.3 version) pcr system  (Thermo Fisher)
90
Thermo Fisher 7500 real-time (2.3 version) pcr system
<t>IL-17F</t> mRNA expression level at different IBD pathological phases, according to the type of IBD (UC or CD) and according to drug history
7500 Real Time (2.3 Version) Pcr System, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/7500 real-time (2.3 version) pcr system/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
7500 real-time (2.3 version) pcr system - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
il 17 secreting cd4 t cells  (STATA Corporation)
97
STATA Corporation il 17 secreting cd4 t cells
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Il 17 Secreting Cd4 T Cells, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 17 secreting cd4 t cells/product/STATA Corporation
Average 97 stars, based on 1 article reviews
il 17 secreting cd4 t cells - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
stata version 17 b e  (STATA Corporation)
99
STATA Corporation stata version 17 b e
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Stata Version 17 B E, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/stata version 17 b e/product/STATA Corporation
Average 99 stars, based on 1 article reviews
stata version 17 b e - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
siemens 7t scanner  (Siemens Healthineers)
90
Siemens Healthineers siemens 7t scanner
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Siemens 7t Scanner, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/siemens 7t scanner/product/Siemens Healthineers
Average 90 stars, based on 1 article reviews
siemens 7t scanner - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
numaris 4 software version 17b  (Siemens Healthineers)
90
Siemens Healthineers numaris 4 software version 17b
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Numaris 4 Software Version 17b, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/numaris 4 software version 17b/product/Siemens Healthineers
Average 90 stars, based on 1 article reviews
numaris 4 software version 17b - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
version 17 b.e  (STATA Corporation)
90
STATA Corporation version 17 b.e
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Version 17 B.E, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 17 b.e/product/STATA Corporation
Average 90 stars, based on 1 article reviews
version 17 b.e - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
pet-17b  (Millipore)
90
Millipore pet-17b
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Pet 17b, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pet-17b/product/Millipore
Average 90 stars, based on 1 article reviews
pet-17b - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
medcalc versión 17  (MedCalc Software Ltd)
90
MedCalc Software Ltd medcalc versión 17
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
Medcalc Versión 17, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/medcalc versión 17/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
medcalc versión 17 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
17.0 windows  (SPSS Inc)
90
SPSS Inc 17.0 windows
Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies <t>of</t> <t>IL-17A</t> + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate <t>percent</t> <t>IL-17A</t> + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the <t>CD4</t> + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 <t>−</t> <t>IL-17</t> + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).
17.0 Windows, supplied by SPSS Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/17.0 windows/product/SPSS Inc
Average 90 stars, based on 1 article reviews
17.0 windows - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


IL-17F mRNA expression level at different IBD pathological phases, according to the type of IBD (UC or CD) and according to drug history

Journal: Gastroenterology and Hepatology From Bed to Bench

Article Title: Evaluation of IL-17B and IL-17F mRNA expression in peripheral blood mononuclear cells and association with clinical outcome of IBD patients

doi:

Figure Lengend Snippet: IL-17F mRNA expression level at different IBD pathological phases, according to the type of IBD (UC or CD) and according to drug history

Article Snippet: For evaluation of IL-17B and IL-17F expression ABI 7500 real-time (2.3 version) PCR system (Applied Biosystems, Foster City, CA, USA) were employed with Takara SYBR Master Mix instructions (Shiga, Japan).

Techniques: Expressing

IL-17B mRNA expression level at different IBD pathological phases, according to the type of IBD (UC or CD) and according to drug history

Journal: Gastroenterology and Hepatology From Bed to Bench

Article Title: Evaluation of IL-17B and IL-17F mRNA expression in peripheral blood mononuclear cells and association with clinical outcome of IBD patients

doi:

Figure Lengend Snippet: IL-17B mRNA expression level at different IBD pathological phases, according to the type of IBD (UC or CD) and according to drug history

Article Snippet: For evaluation of IL-17B and IL-17F expression ABI 7500 real-time (2.3 version) PCR system (Applied Biosystems, Foster City, CA, USA) were employed with Takara SYBR Master Mix instructions (Shiga, Japan).

Techniques: Expressing

Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies of IL-17A + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate percent IL-17A + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the CD4 + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 − IL-17 + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).

Journal: Scientific Reports

Article Title: Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese Patients with Multidrug-resistant Tuberculosis

doi: 10.1038/s41598-017-18200-5

Figure Lengend Snippet: Increased frequencies of CD8 − IFN-γ + cells in PBMCs of MDR-TB patients and decreased frequencies of IL-17A + CD8 − cells, Foxp3 + CD25 + cells during and after rhIL-2 therapy. Flow cytometry measurements of T subset frequencies in PBMCs of patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Stopping and storage gates were set at 30,000 lymphocyte events defined by forward scatter (FSC) and side scatter.Numbers in plots indicate percent IL-17A + CD8 − cells (top left) or CD8 − IFN-γ + cells (top left) in the CD3 + CD8 − gate, with isotype controls were used. For Treg cells staining PE-conjugated anti-human Foxp3 with isotype controls was used (BD Pharmingen™). Foxp3 + CD25 + cells (top right) in the CD4 + CD25 + gate. Frequency of CD3 + CD8 − IFN-γ + T cells was higher in rhIL-2 group ( A ); frequency of CD3 + CD8 − IL-17 + cells was lower in rhIL-2 group ( B ); frequency of CD4 + CD25 + Foxp3 + T cells was lower in rhIL-2 group ( C ); as compared with the control group. Therapy with rhIL-2 facilitated the increasing trend of Th1 frequency, the decreasing trends of Th17 frequency and Treg frequency in the PBMCs from the patients in both groups( D ). Data from 25 cases in control group and 23 cases in the rhIL-2 group were shown using student’s t test or one-way ANOVA with Tukey’s post-hoc test. All reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).

Article Snippet: IL-2 restrictes in vitro generation of IL-17-Secreting CD4 + T cells via STATA-5, IL-2 and STAT5a/b, which were known to be key regulators of Treg cells, also serve to constrain Th17 polarization .

Techniques: Flow Cytometry, Staining, Two Tailed Test

Increased level of IFN-γ mRNA, decreased levels of IL-17A, ROR-γt and FoxP3 mRNA in PBMCs from MDR-TB patients during and after rhIL-2 therapy. Quantitative Real-time PCR analysis of mRNA expression in patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Compared with patients in the control treatment group, patients receiving adjunctive rhIL-2 therapy had lower relative levels of IL-17A mRNA ( A ), ROR-γt mRNA ( B ), Foxp3 mRNA ( C ) and higher relative level of IFN-γ mRNA ( D ) in their PBMCs at the 6-month and 12-month time points during treatment regimens. Using student’s t test or one-way ANOVA with Tukey’s post-hoc test all reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).

Journal: Scientific Reports

Article Title: Clinical and Immunological Effects of rhIL-2 Therapy in Eastern Chinese Patients with Multidrug-resistant Tuberculosis

doi: 10.1038/s41598-017-18200-5

Figure Lengend Snippet: Increased level of IFN-γ mRNA, decreased levels of IL-17A, ROR-γt and FoxP3 mRNA in PBMCs from MDR-TB patients during and after rhIL-2 therapy. Quantitative Real-time PCR analysis of mRNA expression in patients from rhIL-2 group and control group with data from 25 cases in control group and 23 cases in rhIL-2 group were shown. Compared with patients in the control treatment group, patients receiving adjunctive rhIL-2 therapy had lower relative levels of IL-17A mRNA ( A ), ROR-γt mRNA ( B ), Foxp3 mRNA ( C ) and higher relative level of IFN-γ mRNA ( D ) in their PBMCs at the 6-month and 12-month time points during treatment regimens. Using student’s t test or one-way ANOVA with Tukey’s post-hoc test all reported p values are two-tailed and unadjusted for multiple comparisons. (* p < 0.05, ** p < 0.05).

Article Snippet: IL-2 restrictes in vitro generation of IL-17-Secreting CD4 + T cells via STATA-5, IL-2 and STAT5a/b, which were known to be key regulators of Treg cells, also serve to constrain Th17 polarization .

Techniques: Real-time Polymerase Chain Reaction, Expressing, Two Tailed Test